Pharmacological inhibition of GPR35 using TMER1i enhances antitumor immune responses by disrupting Hippo-YAP signaling in T regulatory and cytotoxic T cells, counteracting IDO1-driven immunosuppression in the tumor microenvironment (136). This evidence concerns the gene GPR35 and neoplasm.